PCBL Chemical Fund Raise of ₹448 Cr

PCBL Chemical Earnings Call Transcript: Key Takeaways

Consolidated revenue rose 14% to ₹2,474 Cr and PAT 20% to ₹74 Cr, but volumes fell and the quarter was flattered by a ₹333 Cr US tariff refund.

PCBL Chemical Investor Presentation: Key Takeaways

Q2FY27 consolidated revenue Rs 2,474 Cr (+14% YoY), EBITDA Rs 310 Cr (+12%), PAT Rs 74 Cr (+20%). Strategy: Carbon Black scale-up, Aquapharm specialty growth, advanced battery materials.

PCBL Chemical Annual General Meeting

PCBL Chemical seeks shareholder approval via postal ballot to re-appoint independent director T. C. Suseel Kumar for five years. E-voting runs till 2 December 2026.

PCBL Chemical Q2 FY27 Results: Net Profit ₹74.1 Cr, Up 20.1% YoY

PCBL Chemical Ltd reported revenue from operations of ₹2,474 Cr (+14.4% YoY) and net profit of ₹74.1 Cr (+20.1% YoY) for Q2 FY27.

Key figure

Net profit ₹74.1 Cr · +20.1% YoY

PCBL Chemical Board Meeting Date

PCBL Chemical Ltd intimated that its Board meeting is scheduled for 2 November 2026 to consider unaudited Q1/H1 FY27 results. No decisions have been taken yet.

PCBL Chemical Other Announcement

PCBL Chemical Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI regulatory requirements.

Amba Auto Sales and Services Fund Raise of ₹161.6 Cr

Amba Auto board approved a preferential issue of up to 1.60 crore warrants at Rs 101 each. The issue aggregates Rs 161.60 Crore, subject to shareholder approval.

Value

₹161.6 Cr

Jindal Capital Fund Raise of ₹16.22 Cr

Jindal Capital's board approved a rights issue of 1,08,12,149 shares at Rs.15 each, raising Rs.16.22 Crore. The issue ratio is 3:2, with record date 06 November 2026.

Value

₹16.22 Cr

Rajkot Investment Trust Fund Raise of ₹48 Cr

Rajkot Investment Trust's board approved a Rs 48 Crore rights issue of equity shares. Pricing and record date will be set later by a committee.

Value

₹48.00 Cr

U Y Fincorp Fund Raise of ₹187.2 Cr

U.Y. Fincorp's board approved preferential issues of warrants and equity shares aggregating Rs 187.17 Crore. The issue is subject to shareholder and regulatory approvals.

Value

₹187.2 Cr

Rite Zone Chemcon India Fund Raise of ₹6.58 Cr

Rite Zone Chemcon India announced a preferential issue of 27,69,730 equity shares to 11 investors at Rs.24 each, raising about Rs.6.58 Crore. The approval awaits a shareholder vote on 23 November 2026.

Value

₹6.58 Cr

Sudarshan Pharma Industries Fund Raise of ₹72 Cr

Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.

Value

₹72.00 Cr